A clinical review of studies on bisphosphonate therapy for pediatric osteoporosis has revealed that they increase BMD, but whether they also improve fracture rates or functions of daily life is unclear. Can the findings of this clinical review help inform clinicians whether, when and how to use these agents in children?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Biological Effects of Anti-RANKL Antibody and Zoledronic Acid on Growth and Tooth Eruption in Growing Mice
Scientific Reports Open Access 27 December 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bachrach, L. K. & Ward, L. M. Clinical review: bisphosphonate use in childhood osteoporosis. J. Clin. Endocrinol. Metab. 94, 400–409 (2009).
Letocha, A. D. et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J. Bone Miner. Res. 20, 977–986 (2005).
Marini, J. C. Should children with osteogenesis imperfecta be treated with bisphosphonates? Nat. Clin. Pract. Endocrinol. Metab. 2, 14–15 (2006).
Rauch, F., Travers, R. & Glorieux, F. H. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy. J. Clin. Endocrinol. Metab. 91, 511–616 (2006).
Uveges, T. E. et al. Alendronate treatment of Brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation. J. Bone Miner. Res. [doi:10.1359/jbmr.081238] (2008).
Li, J. S. et al. Economic return of clinical trials performed under the pediatric exclusivity program. JAMA 297, 480–488 (2007).
Whyte, M. P., Wenkert, D., Clements, K. L., McAlister, W. H. & Mumm, S. Bisphosphonate-induced osteopetrosis. N. Engl. J. Med. 349, 457–463 (2003).
Whyte, M. P. et al. Bisphosphonate-induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases. J. Bone Miner. Res. 23, 1698–1707 (2008).
Allen, M. R. & Burr, D. B. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J. Bone Miner. Res. 22, 1759–1765 (2007).
Weinstein, R. S., Robertson, P. K. & Manolagas, S. C. Giant osteoclast formation and long-term oral bisphosphonate therapy. N. Engl. J. Med. 360, 53–62 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Marini, J. Use of bisphosphonates in children—proceed with caution. Nat Rev Endocrinol 5, 241–243 (2009). https://doi.org/10.1038/nrendo.2009.58
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2009.58
This article is cited by
-
Biological Effects of Anti-RANKL Antibody and Zoledronic Acid on Growth and Tooth Eruption in Growing Mice
Scientific Reports (2019)
-
Bisphosphonate Treatment of Children and Adults with Osteogenesis Imperfecta: Unanswered Questions
Calcified Tissue International (2015)
-
Causes, mechanisms and management of paediatric osteoporosis
Nature Reviews Rheumatology (2013)
-
New perspectives on osteogenesis imperfecta
Nature Reviews Endocrinology (2011)
-
Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment
Osteoporosis International (2011)